A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Cedars-Sinai Cancer: Erasing LGBTQ+ Healthcare Disparities

By Examining the Intersection of Sexual Orientation, Gender and Cancer, Cedars-Sinai Cancer Specialists Aim to Better Prevent, Detect, Treat and Cure Cancer

A first-of-its-kind LGBTQ+ cancer symposium opens this week as part of Cedars-Sinai’s effort to equalize healthcare access and treatment for all–including patients who identify as LGBTQ+.

Studies have shown that the way LGBTQ+ patients are screened, diagnosed and treated for cancer may put them at a significant disadvantage compared to cisgender heterosexual patients.  

To help overcome these disparities in healthcare, teams at Cedars-Sinai Cancer-and across the broader health system-are uniting to better include the science and voices of LGBTQ+ people on cancer care, community engagement and policies that influence health disparities. 

“We recognize that by examining the intersection of sexual orientation, gender and cancer, we can better prevent, detect and cure cancer,” said B.J. Rimel, MD, a gynecological oncologist and medical director of the Cedars-Sinai Cancer Clinical Trials Office. “To make meaningful change, we must continue to ask ourselves where the disparities are, then identify how best to address them. While this process can be challenging, recognizing disparities is the first step to repairing them.”

To address these needs, Rimel and Cedars-Sinai Cancer leadership-including Dan Theodorescu, MD, PhD, director of Cedars-Sinai Cancer-are hosting a first-of-its-kind LGBTQ+ cancer symposium, taking place in Los Angeles on June 2-3.

“We must build national and international awareness to the specific cancer issues that affect our LGBTQ+ patients and discuss how to overcome barriers that impede the best care,” said Theodorescu, the PHASE ONE Foundation Distinguished Chair and professor of Surgery and Pathology and Laboratory Medicine. “We aspire to transform the practice of medicine by advancing and applying science and striving for a better understanding of all aspects of diversity. In doing so, we can achieve the highest impact.”

The Cedars-Sinai Newsroom spoke to Rimel, also associate professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology at Cedars-Sinai Cancer, to learn more about Cedars-Sinai’s efforts to eradicate disparities in LGBTQ+ care.

Newsroom: What inequities, or disparities, exist in the LGBTQ+ cancer community?
Rimel: One of the clearest examples is in gendered cancer screening. We think of mammography as one of the most powerful tools we have against breast cancer. But if a person whose gender doesn’t fit that of a cisgender female walks into a mammography suite-or a community screening event-they might not be offered appropriate screening, or they might even receive suboptimal care.

Another example common in gynecological oncology is when a transmasculine patient calls the office in need of a pelvic ultrasound. The medical office staff might assume the patient, who has a male voice, called the wrong office, and direct them elsewhere without listening to their questions or concerns.  

Newsroom: How can data, advanced education and better communication solve these problems?
Rimel: If the medical office staff member who answered the phone knew this patient was transmasculine-because his patient records indicated this-they could have answered the phone saying, “Hello, sir. Can I help schedule your pelvic ultrasound?”

Capturing the data-including patient preferences and goals-and ensuring care teams have access to this data, are ways to undo inequities.

Newsroom: How is Cedars-Sinai Cancer helping lead the paradigm change across the medical center?
Rimel: Within our electronic medical records, Cedars-Sinai has an option for patients to identify as multiple gender orientations, sexual orientations and sexual partner preferences. Capturing this information is one part of the solution.

The other key element is educating providers to ask those hard questions and get comfortable using the correct language when they are asking them. Continuing education and an openness to learn is critical.

Newsroom: What are the key takeaways that you hope medical professionals will learn at the Cedars-Sinai LGBTQ+ Cancer Symposium?  
Rimel: I want medical professionals to walk away with two things. First, to understand it’s OK to ask questions and to approach conversations with LGBTQ+ patients with humility and curiosity.

The second takeaway is a call for medical professionals and care teams to understand the disparities. While enormous strides have been made, LGBTQ+ cancer patients don’t benefit from the same privileges or opportunities as other patients. As doctors, we have to be accountable for understanding what policies exist-and how they impact all of our patients, including those who identify as LGBTQ+.

To register or learn more about the upcoming LGBTQ+ Cancer Symposium, taking place in person and virtually, click here

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy